Binge eating (BE) is a heritable symptom of eating disorders with an unknown genetic etiology. 32
INTRODUCTION 53
Binge eating (BE) is operationally defined as the consumption of a relatively large amount 54 of food over a short period of time, and is accompanied by feelings of loss of control (Amianto, 55 Ottone, Abbate Daga, & Fassino, 2015) . Repeated BE that occurs at least once per week for at 56 least three months is termed binge eating disorder (BED). BE has a lifetime prevalence of 57 approximately 4.5% (Hudson, Hiripi, Pope, & Kessler, 2007) and is associated with a number of 58 comorbid behavioral, mood, and physical disorders such as substance abuse, depression, 59 obesity, and chronic pain (Bulik & Reichborn-Kjennerud, 2003; Citrome, 2017; Hudson et al., 60 2007) . Although there is no sex difference in the lifetime prevalence of BE, women are nearly 61 twice as likely as men to progress to the more severe BED (3.5% vs. 2.0% respectively (Hudson 62 et al., 2007) . However, the etiology of this sex difference is not known. amygdala-hippocampus complex in AN, and greater frontal cortical response to food stimuli in 69 BED (Geliebter et al., 2006) . Another important neuroanatomical change common to multiple 70 types of ED involves changes in myelin which is the lipid-rich, membranous insulation sheath that 71 extends from oligodendrocytes to the axons and is involved in axon maintenance (via 72 oligodendrocyte signaling) and function, including rapid salutatory conduction of action potentials. 73 BN is associated with a reduction in fractional anisotropy, a brain imaging measure of white matter 74 integrity, in the corona radiata and corpus callosum (Mettler, Shott, Pryor, Yang, & Frank, 2013 ) 75 as well as in forceps major and minor, inferior fronto-occipital, superior longitudinal, and uncinate 76 fasciculi, corticospinal tract, and cingulum (He, Stefan, Terranova, Steinglass, & Marsh, 2016) . In 77 women with AN, a reduced fractional anisotropy relative to controls was reported in left superior 78 4 longitudinal fasciculus (Via et al., 2014) . Importantly, previous results found no differences in white 79 matter integrity between healthy controls and women who have recovered from AN (Yau et al., 80 2013) , indicating that decreased myelination is a reversible consequence rather than a cause of 81 aberrant eating behavior in ED. Additionally, both obese women and men show a decrease in 82 myelination in obesity, but only in women did reduced myelin correlate with BMI and leptin levels 83 (Mueller et al., 2011) , suggesting potential sex differences in the contribution of demyelination to 84 negative health consequences of eating disorders. 85
Using transcriptome analysis via mRNA sequencing (RNA-seq), we previously showed 86 that BE of sweetened palatable food (PF) relative to chow controls induced a downregulation of 87 several genes enriched for myelination, axon ensheathment, and oligodendrocyte formation and 88 differentiation, providing evidence that, similar to BN and AN, decreased myelination is a 89 consequence of BE in our preclinical model (Kirkpatrick et al., 2017) . However, because 90 transcriptome analysis is conducted at the mRNA level, it is not known whether the BE-induced 91 decrease in myelin-associated transcripts translates to a decrease in myelin proteins. 92 Furthermore, whether decreasing myelin levels could induce or enhance BE has not been tested. 93
In the present study, we tested the hypothesis that administration of the demyelinating 94 agent cuprizone (a.k.a. cyclohexylidene hydrazide) in C57BL/6 mice (Hiremath et al., 1998) would 95 induce BE in the BE-resistant C57BL/6J (B6J) substrain and enhance BE in the BE-prone 96 C57BL/6NJ (B6NJ) substrain (Kirkpatrick et al., 2017) . Laboratory chow containing 0.3% 97 cuprizone has previously been shown to induce a significant decrease in myelination of the corpus 98 callosum at 4 weeks and complete demyelination after six weeks (Hiremath et al., 1998) and two-99
week exposure of 0.2% cuprizone has been shown to be sufficient to induce nearly complete 100 demyelination in mice (Doan et al., 2013) . At the completion of the study, we harvested brain 101 7 porcelain dish was placed in the far corner of the chamber during this time. allowed free access to both sides. A non-porous ceramic bowl containing forty, 20 mg PF pellets 169 was placed in the center of the light side. Mice were initially placed on the light side facing both 170 the food and the doorway and were video recorded for 30 min. Because the light side is aversive, 171 increased behaviors in this environment were operationalized as compulsive-like, including 172 compulsive-like eating. 173
On D24, brains were extracted and punches of the left and right striatum were harvested 174 and combined as previously described (Kirkpatrick et al., 2017; Yazdani et al., 2015) , flash frozen 175 on acetone and dry ice, and stored at -80°C until western blotting procedures commenced. We 176 chose to examine the striatum because this is the tissue in which we originally identified the 177 downregulation of transcripts coding for genes associated with oligodendrocyte differentiation and 178 myelination (Kirkpatrick et al., 2017) . Cuprizone treatment has been shown to induce multiple 179 signs of demyelination in the striatum, including the hallmark cuprizone effects of a decrease in 180 MBP and other myelin proteins as well as an increase in astrogliosis (via GFAP) and microgliosis 181 (via IBA1) in female C57BL/6N mice (Beckmann et For MAG detection, blots were incubated in a 1:5,000 dilution of anti-MAG antibody (EMD 194 Millipore, Burlington, MA, USA, #MAB1567) in 5% BSA in TBST overnight at 4C, then a 1:10,000 195 dilution of peroxidase conjugated donkey anti mouse antibody (Jackson Immunoresearch, West 196
Grove, PA, USA, #715-035-151). For MBP detection, blots were incubated in a 1:10,000 dilution 197 of anti-MBP antibody (EDM Millipore, #MAB 386) in 5% BSA in TBST overnight at 4C, then a 198 1:10,000 dilution of peroxidase conjugated donkey anti rat antibody (Jackson Immunoresearch 199 #712-035-153) for one hour. After probing, all blots were imaged using Clarity ECL (BioRad, #170-200 5061) and a c300 imager (Dublin, CA, USA). 201
Blots were then stripped (Thermo Scientific, 46430) at 55°C for 30 min, reblocked with 5% 202 BSA in TBST, incubated in 1:50,000 Beta-actin antibody (Sigma Aldrich, St, Louis, MO, USA, 203 #A2228) in 5% BSA in TBST for 1 h, and then a 1:10,000 dilution of peroxidase conjugated donkey 204 anti mouse antibody for 1 h. Blots were then reimaged for beta actin. Densitometry was conducted 205
using ImageJ, and each lane was normalized to its respective densitometry value for beta actin. 206
Each lane was then normalized to the average wild-type value of that particular blot and then 207 finally, data were combined across blots and statistical analysis was run in R as described below. 208 9 209 210
Statistical analysis 211
We analyzed food consumption in R (https://www.r-project.org/) using mixed model 212
ANOVAs with Genotype, Sex, and Treatment as independent variables, and Day as a repeated 213 measure. When the data were separated by Sex, mixed model ANOVAs were employed with 214
Genotype and Treatment as independent variables, and Day as a repeated measure. Bonferroni-215 adjusted post hoc pairwise unpaired t-tests were used to determine whether group differences 216 were significant on individual days. Slope analyses were conducted as previously described (R. 
Cuprizone treatment induces weight loss in female and male B6J and B6NJ mice 222
We employed a regimen consisting of one week of habituation to the colony, two weeks 223 of the cuprizone diet, three weeks of recovery from cuprizone, and four weeks of training for BE 224 of PF ( Fig.1) . A single cuprizone-assigned male B6J mouse died early on during the study. 225
Therefore, the results are presented for 63 mice instead of 64 mice. In examining the sex-226 combined dataset, we found significantly lower body weight in cuprizone-treated mice of both the 227 B6J and B6NJ strains on D8-D14 of cuprizone treatment ( Fig.2A ). Remarkably, within 24 h after 228 the cuprizone diet was replaced with standard laboratory chow (D15), mice regained nearly all of 229 their body weight and did not differ significantly from control mice ( Fig.2A) . 230
When considering the female and male datasets separately, females showed significant 231 weight loss earlier on at D4 and D5 ( Fig.2B ) and both sexes showed a significant reduction in 232 body weight from D8-D14, after which there was recovery of weight loss within 24 following 233 removal of the cuprizone diet and replacement with normal home cage chow ( Fig.2B,C) . 234
Cuprizone treatment reduces BE and compulsive-like eating in male but not female mice 235 of the BE-prone B6NJ substrain 236
Consistent with our previous report (Kirkpatrick et al., 2017) , B6NJ mice showed greater 237 overall PF consumption compared to B6J mice (Fig.3 ) -a behavior that we previously showed 238 was associated with an enrichment of downregulated genes involved in myelination in the striatum 239 (Kirkpatrick et al., 2017) . However, contrary to our hypothesis that the demyelinating agent 240 cuprizone would increase BE, prior treatment with cuprizone in the BE-prone B6NJ substrain 241 actually decreased the amount of PF intake and decreased the slope of escalation in PF intake 242 intake across days (Fig.3A,B ). Despite the lack of effect of cuprizone on the amount of PF intake 246 in B6J mice, cuprizone induced a small but significant non-zero slope in escalation of PF intake 247 across days ( Fig.3B ). In examining compulsive-like PF intake in the light/dark conflict test on D23, 248 as expected, the BE-prone B6NJ strain showed a significant increase in PF intake relative to the 249 BE-resistant B6J strain; however, there was no effect of cuprizone or interaction with substrain in 250 the sex-combined dataset ( Fig.3C ). 251
In examining females only, there was no significant effect of the cuprizone diet on PF 252 consumption or compulsive-like PF intake ( Fig.3D,F ). However, there was a small but significant 253 increase in the slope of escalation of PF intake in cuprizone-treated B6J females due to the uptick 254 in PF intake on the final day of BE training (D18; Fig.3D,E) . Furthermore, the escalation in 255 cuprizone-treated B6J females was significantly greater than control B6J females (#p = 0.045; 256
Fig.3D). 257
In examining males only, cuprizone-treated B6NJ mice showed a robust reduction in PF 258 intake relative to their control B6NJ counterparts ( Fig.3G ). Additionally, cuprizone treatment 259 eliminated the slope in escalation of PF intake ( Fig.3H ) and significantly reduced compulsive-like 260 11 PF intake in B6NJ males in the light/dark conflict test ( Fig.3I ). Thus, the cuprizone-induced 261 reduction of PF intake in the sex-combined dataset was completely accounted for by male B6NJ 262
mice. 263
In examining locomotor activity on D23 in the light side of the light/dark test for compulsive-264 like eating, there was a main effect of Genotype (F1,55 = 4.72; p = 0.034) and Sex (F1,55 = 3.97; 265 p = 0.051) but no effect of Treatment [F(1,55) = 0.03; p = 0.86) and no interactions (ps > 0.54) 266
(data not shown). In examining time spent in the light-paired side, there was also no effect of 
Effect of cuprizone on locomotor activity on D1 during initial preference assessment and 271 on D22 during PF-CPP assessment 272
We did not observe any evidence for a potential confounding influence of cuprizone 273 treatment on locomotor activity that could explain differences in PF intake. Specifically, in 274 considering the sex-combined dataset for D1 locomotor activity during initial preference for the 275 PF-paired side (5 weeks after the beginning of cuprizone treatment or i.e., three weeks after the 276 termination of cuprizone treatment), there was no effect of Substrain or interaction with Treatment 277 ( Fig.4A ,C,E). In considering the sex-combined dataset for D22 locomotor activity during 278 assessment of PF-CPP, there was a significant Genotype x Treatment x Sex interaction that was 279 explained by a small but significant decrease in locomotor activity in cuprizone-treated B6J 280 females ( Fig.4B ,D,F) in the absence of any significant effect of PF intake (see Fig.3D ). 281
In examining PF-CPP via the change in time spent on the PF-paired side between D1 and 282 D22 (D22-D21; s), there was no effect of Genotype [F(1,55) = 0.01; p = 0.91], Treatment [F(1,55) 283 = 0.47; p = 0.50], Sex [F1(55) = 0.96; p = 0.33], or any interactions (ps > 0.41). In an additional 284 analysis of PF-CPP, we included Day as a repeated measure in a mixed effects ANOVA and in 285 this case, we observed an overall effect of Day [F(1,55) = 6.74; p = 0.012] but no effect of 286 12 Genotype [F(1,55) = 0.056; p = 0.82], Treatment [F(1,55) = 0.64; p = 0.43], Sex [F(1,55) = 0.69; 287 p = 0.41], or any interactions (ps > 0.37) (data not shown). 288 289
Effect of cuprizone on myelin proteins in the striatum 290
We previously reported a BE-induced downregulation of a gene network enriched for 291 myelinationan effect that was driven by the BE-prone B6NJ substrain (Kirkpatrick et al., 2017) . 292
Here, we examined differences in the myelin proteins MAG and MBP in B6NJ versus B6J mice 293 and the effect of cuprizone on these protein levels. There were no effect of cuprizone treatment 294 or substrain on MAG levels ( Fig.5A,B ). However, for MBP, cuprizone treatment induced a 295 significant decrease in total MBP and in each of the MBP isoforms compared to control mice 296 The demyelinating agent cuprizone induced comparable weight loss in females and males 303 of both the BE-resistant B6J substrain and the BE-prone B6NJ substrain (Figs.1,2), yet it induced 304 robust substrain-and sex-dependent effects on PF intake. In contrast to our hypothesis that 305 administration of the demyelinating agent cuprizone would enhance BE, we observed the 306 opposite result -a robust reduction in BE in male but not female mice of the BE-prone B6NJ strain 307 contributes to the high mortality rates in cuprizone doses exceeding 0.3% (Hiremath et al., 1998; 314 Stidworthy et al., 2003) . The mechanism behind cuprizone-induced weight loss is unclear, but 315 could involve copper chelation, given that copper deficiency in both rats (C. G. Taylor, Bettger, & 316 Bray, 1988) and mice (Prohaska, 1983 ) results in reduced body weight. In the present study, we 317 report a similar degree of weight loss in both female and male cuprizone-treated mice of both 318 substrains (Fig. 2) . Thus, it is unlikely that weight loss alone is responsible for the male-specific 319 reduction in BE and compulsive-like eating in the BE-prone B6NJ substrain. Also, food restriction-320 induced weight loss promotes rather than reduces BE in rodents ( Herman, & Beal, 1994), further suggesting that the reduction in PF consumption by cuprizone 323 treatment is not likely caused by the weight loss that occurred three weeks prior to BE training. 324
In contrast to our original hypothesis, the demyelinating agent cuprizone produced very 325 little effect in the BE-resistant B6J strain (although note the small but statistically significant 326 increase in the slope of PF intake in cuprizone-treated B6J females versus their control B6J 327 female counterparts; Fig.3D ), nor did it enhance BE in the BE-prone strain (Kirkpatrick et al., 328 2017) . Instead, cuprizone reduced BE in the BE-prone B6NJ strain and it did so only in male mice 329 ( Fig.3 ). This are several potential explanations underlying the substrain-and sex-dependent 330 effect. Perhaps males are more sensitive to the ingestive and/or post-ingestive aversive 331
properties of the cuprizone diet (e.g., taste, nausea) and show a learned, generalization effect on 332 PF intake during BE. However, this explanation cannot account for the similar rate of body weight 333 recovery in females and males following replacement of the home cage cuprizone diet with home 334 cage chow (Fig.2B,C) . Another possibility is that cuprizone induced a selective change in the 335 perception or the hedonics of sweet taste in males. Indeed, only the cuprizone-treated B6NJ 336 males initially consumed less PF than their control B6NJ male counterparts on the very first PF 337 training day [t(14) = 2.47; p = 0.027; Fig.3G ]. However, despite this initial reduction in PF intake, 338 14 the cuprizone-treated B6NJ males showed a sharp escalation in PF intake from the first to the 339 second training day, after which they plateaued rather than continuing to escalate like their control 340 B6NJ male counterparts (Fig.3G,H) . It is also possible that cuprizone induced an anhedonic-like 341 state selectively in B6NJ males that caused a reduction in PF intake (Sen et al., 2019) or, e.g., 342
novelty-induced hypophagia due to a depressive-like effect (Dulawa & Hen, 2005) . 343
Here, we showed that two weeks of exposure to the cuprizone diet induced a significant 344 reduction in the level of MBP when assessed at nearly nine weeks after the beginning of cuprizone 345 without affecting MAG at the time of assessment, irrespective of Sex or Substrain (Fig.5) . MBP 346 is a major structural protein produced by oligodendrocytes and Schwan cells and redistributes to 347 the processes to initiate axon ensheathment, compaction, thickening, and adhesion (Han, following the beginning of cuprizone treatment as the process of remyelination ensued (Ludwin & 363 Sternberger, 1984) . It is also possible that there are brain region-specific changes in myelin-364 15 associated proteins and that the striatum shows a different profile than, e.g., the corpus callosum 365 which is the hallmark tissue that is typically employed to assess the degree of cuprizone-induced 366
demyelination. 367
We observed a decrease in MBP in the BE-prone B6NJ substrain versus BE-resistant B6J 368 substrain that was significant for the14 kDa isoform ( Fig.5) and was consistent with our previous 369 observation of an association of BE with the downregulated expression of a set of genes enriched 370 for myelination (Kirkpatrick et al., 2017) . In that study, the enrichment was identified as a function An additional factor that could contribute to sex differences in the effect of cuprizone on 392 BE is weight loss-induced rebound hyperphagia. We are unaware of any studies demonstrating 393 sex differences in eating behavior after weight loss in rodentswith or without cuprizone. 394
However, greater hyperphagia has been reported in females compared to males after 395 hypothalamic lesions in rats (Valenstein, Cox, & Kakolewski, 1969) and Il18 deletion in mice 396 (Zorrilla et al., 2007) . Moreover, when rats were acutely fasted (12 hours), males showed a 397 modest increase in food consumption in the 24 h post-fast, while females showed a robust 398 increase in consumption that was significantly greater than that of the males (Gayle, Desai, 399 Casillas, Beloosesky, & Ross, 2006) . In a closer examination of our data, although both females 400 and males treated with cuprizone showed similar reductions in body weight and similar regaining 401 of body weight to pre-cuprizone levels (Fig.2) , B6NJ females showed a faster percent body weight 402 increase compared to B6NJ males during the first 24 h after the cuprizone diet was replaced with 403 the normal chow diet [KEITH: t(df)= 2.5; p = 0.02; data not shown), providing some evidence for 404 slower rebound hyperphagia in B6NJ males that could extend to less acute and escalated PF 405 intake in the 30 min training trials. 406
Another potential factor explaining the male-specific reduction in BE with cuprizone could 407 involve sex differences in the demyelinating effects of cuprizone and/or the process of 408 remyelination. Previous reports have found no significant sex difference in cuprizone-induced 409 demyelination in C57BL/6J mice (L. C. Taylor, Gilmore, Ting, & Matsushima, 2010). However, a 410 separate study in the SJL inbred mouse strain showed less severe cuprizone-induced 411 demyelination and loss of oligodendrocytes in female SJL and Swiss Webster mice (Ludwin, 412 1978 ; L. C. Taylor, Gilmore, & Matsushima, 2009) which is consistent with the lack of significant 413 behavioral effects observed with B6NJ females in the current study. Given that we used a different 414 cuprizone regimen and importantly, given that we observed a sex difference in cuprizone 415 17 behavioral effects in a different genetic B6 substrain (B6NJ), it is possible that B6NJ female mice 416 are less sensitive to cuprizone-induced demyelination which in turn could explain the lack of 417 behavioral effect. However, our current immunoblotting results with MAG and MBP fail to support 418 this hypothesis as we did not identify any significant Sex effects or Sex-interactive effects at nearly 419 nine weeks after the beginning of cuprizone treatment. Assessment of myelin proteins via 420 immunoblot and immunohistochemical procedures at multiple earlier time points (e.g., starting at 421 five weeks) (Doan et al., 2013) and in multiple brain regions could address whether the enhanced 422 behavioral effects of cuprizone in B6NJ males are supported by enhanced or earlier 423
demyelination. 424
To summarize, we observed a male-specific reduction in BE in the BE-prone B6NJ 425 substrain in response to the demyelinating agent cuprizone. These results suggest that sex-426 specific neurobiological mechanisms could underlie BE in a manner that depends on genetic 427 background. Future studies employing additional and more selective demyelination/remyelination 428 strategies in a spatiotemporal manner on multiple genetic backgrounds are necessary to test the 429 contribution of sex differences in myelin dynamics in the establishment of and recovery from BE. Mice then received either ad libitum standard laboratory chow or ad libitum cuprizone-treated lab 447 diet for two weeks. After removal of cuprizone treatment, all mice were given ad libitum standard 448 laboratory chow for three weeks. Finally, in weeks 7-10, training for binge eating (BE) commenced 449 with continued ad libitum access to normal chow minus the 30 min training sessions with palatable 450 food (PF). Mice were tested for side preference in the CPP chamber before and after training (D1 451 and D22) for BE of PF. On D2, 4, 9, 11, 16, and 18, mice were confined to the right side of the 452 chamber with access to PF. On D3, 5, 10, 12, 17, and 19, mice were confined to the left side of 453 the chamber with an empty food bowl. On D23, the light/dark conflict test was conducted for 454 compulsive-like PF consumption. On D24, brains were harvested, flash frozen, and stored at - 4.44, 4.41, 4.65, 5.10, 5.50; *p = 2.8 x 10 -4 , 1.2 x 10 -4 , 1.3 x 10 -4 , 6.7 x 10 -5 , 1.9 x 10 -5 , 6.3 x 10 -6 ; 470 20 αadjusted = 0.05/16 = 0.0031; B6NJ cuprizone vs. B6NJ control: t(30) = 4.52, 4.72, 5.10, 6.03, 5.95, 471 5.55; *p = 9.0 x 10 -5 , 5.1 x 10 -5 , 1.8 x 10 -5 , 1.6 x 10 -6 ; αadjusted = 0.0031]. B) In females, there was 472 an effect of Treatment [F(1,28) = 47.21; p = 1.8 x 10 -7 ] but no effect of Substrain [F(1,28) = 1.99; 473 p = 0.17] and no interaction [F(1,28) = 1.85; p = 0.19]. Additionally, there was an effect of Day 474 9.23, 10.25, 12.08, 11.65, 12.42, *p = 1.1 x 10 -4 , 4.7 x 10 -5 , 2.6 x 10 -7 , 2.5 x 10 -7 , 6.9 x 10 -8 , 8.6 x 478 10 -9 , 1.4 x 10 -8 , 6.0 x 10 -9 , ; αadjusted = 0.0031]. Similarly, cuprizone-treated B6NJ females also 479 weighed less than control B6NJ females on D4-D14 [t(14) = 4.46, 5.17, 6.53, 11.23, 11.45, 10.90, 480 10.64, 11.02; *p = 5.4 x 10 -4 , 1.4 x 10 -4 , 1.3 x 10 -5 , 2.2 x 10 -8 , 1.7 x 10 -8 , 3.2 x 10 -8 , 4.3 x 10 -8 , 2.8 481 cuprizone-treated B6NJ males also weighed less than control B6NJ males on D8-D14 [t(14)= 487 6.55, 7.04, 7.60, 8.59, 7.48, 7.64; *p = 1.3 x 10 -5 , 5.9 x 10 -6 , 2.5 x 10 -6 , 5.9 x 10 -7 , 3.0 x 10 -6 , 2.3 x 488 10 -6 ; αadjusted = 0.0031]. females, there was a main effect of Substrain [F(1,28) = 11.65; #p = 0.002] but no effect of 526 Treatment [F(1,28) = 0.049; p = 0.83] and no interaction [F(1,28) = 0.031; p = 0.86]. The effect of 527 Substrain was explained by greater overall PF intake in B6NJ females versus B6J females (#). expected greater locomotor activity than males [F(1,55) = 7.84; p = 0.0071] but no effect of 548 23 Genotype [F(1,55) = 1.29; p = 0.26], Treatment [F(1,55) = 3.08; p = 0.085], or any interactions (p 549 > 0.086). (B,D,F): In examining locomotor activity on D22 over 30 min, there was no effect of 550 Genotype [F(1,55) = 2.26; p = 0.14], Treatment [F(1,55) = 0.32; p = 0.57], or Sex [F(1,55) = 3.30; 551 p = 0.075]. However, there was a significant Genotype x Treatment x Sex interaction [F(1,55) = 552 4.99; p = 0.030]. To determine the source of this three-way interaction on D22, we analyzed 553 females and males separately. (D): For D22 locomotor activity in females, there was a main effect 554 of Genotype [F(1,28) = 6.86; p = 0.014], no effect of Treatment [F(1,28) = 0.38; p = 0.55], and a 555 significant Genotype x Treatment interaction [F(1,28) = 6.94; p = 0.014]. The source of the 556 interaction was explained by cuprizone-treated B6J females showing less locomotor activity on 557 D22 than control B6J females [t(14) = 2.23; p = 0.043]. For males, there was no effect of Genotype 558 . (B,C) : For MAG protein, there was 564 no effect of Cuprizone Treatment [F(1,54) = 0.47; p = 0.49], Substrain [F(1,54) = 2.28; p = 0.14], 565
Sex [F(1,54) = 2.87; p = 0.10] or any interactions (ps > 0.34). The lack of effect of Treatment and 566
Substrain on MAG protein levels is shown graphically in panels B and C as a comparison with 567 MBP (below). (D): For total MBP protein, there as an effect of Treatment [F(1,54) = 20.96; p = 2.8 568
x 10 -5 ] and a nearly significant effect of Substrain [F(1,54) = 3.72; p = 0.059] but no effect of Sex 569 [F(1,54) = 0.15; p = 0.70] and no interactions (ps > 0.14). For the 21 kDa band, there was a main 570 effect of Treatment [F(1,54) = 8.06; p = 0.0064] but no effect of Substrain [F(1,54) = 1.90; p = 571 0.17], Sex [F(1,54) = 0.012; p = 0.91], or any interactions (ps > 0.10). For the 18.5 + 17 kDa 572 bands, there was a main effect of Treatment [F(1,54) = 17.42; p = 0.00011] and a nonsignificant 573 effect of Substrain [F(1,54) = 3.29; p = 0.075] but no effect of Sex [F(1,54) = 0.078; p = 0.78] and 574 24 no interactions (ps > 0.15). For the 14 kDa band, there was an effect of Treatment [F(1,54) = 575 40.24; p = 4.8 x 10-8] and Substrain [F(1,54) = 7.8; p = 0.0072] but no effect of Sex [F(1,54) = 576 0.98; p = 0.33] and no interactions (ps > 0.11). (D): To follow up on the Treatment effects, unpaired 577 t-tests for the total, 21 kDa, 18/17 kDa, and 14 kDa MBP bands indicated a significant decrease 578 in MBP for all bands [t(60) = 4.56, 2.87, 4.19, and 6.00; p = 2.6 x 10 -5 , 0.0057, 9.3 x 10 -5 , 1.2 x 10 -579 7 , respectively]. (E): To follow up on the trending Substrain effect, unpaired t-tests for the total, 21 580 kDa, 18.5/17 kDa, and 14 kDa MBP bands indicated a significant decrease in the immunostaining 581 of the 14 kDa band (*) in the B6NJ strain (N) [t(60) = 1.82, 1.42, 1.76, and 2.32; p = 0.073, 0.16, 582 0.084, and *0.024, respectively].
